Abdalmalik Bin Khunayfir
Neurology · Newnan, GANPI 1386291284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $598, 4.9 times the $122 reported in 2021. That places this record below the midpoint for neurology clinicians in GA, where the typical reported total is $1,471.
Across 65 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$261
- UCB, Inc.$235
- EMD Serono, Inc.$134
- Johnson & Johnson$117
- Sanofi$96
- AbbVie$91
- plus $538 from 19 others
What the payments were for
- Food & beverage$1,27693%
- Education$997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $261 |
| UCB, Inc. | 6 | $235 |
| EMD Serono, Inc. | 9 | $134 |
| Johnson & Johnson | 2 | $117 |
| Sanofi | 5 | $96 |
| AbbVie | 4 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| TG Therapeutics, Inc. | 2 | $53 |
| Biogen | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Acadia Pharmaceuticals Inc | 1 | $30 |
| GE HealthCare | 1 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $29 |
| CSL Behring | 1 | $29 |
| Neurelis, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Argenx US, Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Averitas Pharma Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $14 |
How this compares
$1,471 in reported general payments places this provider in the 45th percentile of 506 neurology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 26 | $750 |
| Gabapentin | 36 | $717 |
| Prednisone | 13 | $53 |
Paid to pharmacies, not to this prescriber.
Other neurology in Newnan
- Gathline EtienneNewnan$128K
- Qing NiNewnan$42K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.